AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17329061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181
Study 16224680 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) patients
Number of subjects: 43
Study 16224680 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study 12403858 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based asthma education program (8 weekly sessions)
Number of subjects: 95
Study 12403858 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study 10547391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (200 mg/day for 5 years)
Number of subjects: 2972
Study 10547391 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2972
Study 8636520 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP of 5 cm H2O (PEEP) with flow-by trigger mode
Number of subjects: 12
Study 8636520 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP of 5 cm H2O (PEEP) with demand-valve trigger mode
Number of subjects: 12
Study 8636520 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP)
Number of subjects: 12
Study 8636520 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-by trigger mode
Number of subjects: 12
Study 8636520 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-valve trigger mode
Number of subjects: 12
Study 2179478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin (BCG) therapy administered in weekly scarifications up to 3 years
Number of subjects: 48
Study 2179478 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control group)
Number of subjects: 48
Study 2179478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin (BCG) therapy
Number of subjects: 48
Study 7471341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg buccally)
Number of subjects: 15
Study 7471341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31923061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus ketorolac
Number of subjects: 71
Study 31923061 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 71
Study 30391194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selexipag
Number of subjects: 34
Study 27764781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by IV cisplatin and vinorelbine chemotherapy
Number of subjects: 16
Study 25873050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron treatment at 6 mg/kg/day plus dietary advice
Number of subjects: 150
Study 25873050 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dietary advice
Number of subjects: 150
Study 23564916 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1184
Study 23564916 — intervention group
Group type: COMPARATOR
Intervention: n-3FA supplement
Number of subjects: 1184
Study 23564916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study 21269779 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg hydrocortisone
Number of subjects: 63
Study 21269779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 18506446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 40 mg Depo-Medrol soaked Gelfoam applied over the affected nerve root after discectomy
Number of subjects: 57
Study 18506446 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 57
Study 17214891 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit computer-based decision aid (DARTS II)
Number of subjects: 29
Study 17214891 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit computer-based decision aid (DARTS II)
Number of subjects: 29
Study 17214891 — intervention group
Group type: COMPARATOR
Intervention: Paper-based guidelines (control)
Number of subjects: 29
Study 17214891 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms of the trial
Number of subjects: 29
Study 17214891 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based decision aids
Number of subjects: 29
Study 16813586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pre-operative chemoradiotherapy (CRT)
Number of subjects: 0
Study 15459400 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening approach
Number of subjects: 0
Study 15459400 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for chlamydia in men
Number of subjects: 0
Study 10916444 — intervention group
Group type: EXPERIMENTAL
Intervention: GB + C (gastric band with cuff)
Number of subjects: 80
Study 10916444 — intervention group
Group type: COMPARATOR
Intervention: GB - C (gastric band without cuff)
Number of subjects: 80
Study 8832772 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG-2766 (40 mg/day)
Number of subjects: 0
Study 1485505 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-one block with general anesthesia
Number of subjects: 182
Study 1485505 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 182
Study 3917702 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride supplementation (64 mmol potassium chloride a day)
Number of subjects: 20
Study 3917702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29978378 — intervention group
Group type: EXPERIMENTAL
Intervention: RBE-enriched porridge (35 g, including 2 g RBE) with water
Number of subjects: 12
Study 29978378 — intervention group
Group type: EXPERIMENTAL
Intervention: RBE-enriched porridge (35 g, including 2 g RBE) with milk
Number of subjects: 12
Study 29978378 — intervention group
Group type: EXPERIMENTAL
Intervention: RBE oil (2 g)
Number of subjects: 12
Study 29978378 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 12
Study 28410760 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal glove and gown use
Number of subjects: 0
Study 28410760 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in hand hygiene compliance
Number of subjects: 0
Study 28410760 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in HCW-patient contact rates
Number of subjects: 0
Study 25348594 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic fundoplication
Number of subjects: 47
Study 25348594 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 47
Study 25348594 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 47
Study 25348594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment options (endoscopic fundoplication and PPI therapy)
Number of subjects: 47
Study 23059790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methylprednisolone acetate (MPA) 60 mg + lidocaine 60 mg
Number of subjects: 10
Study 23059790 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 60 mg only (Control)
Number of subjects: 10
Study 22093120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alpha inhaled after airway clearance techniques
Number of subjects: 20
Study 22093120 — intervention group
Group type: COMPARATOR
Intervention: Dornase alpha inhaled before airway clearance techniques
Number of subjects: 20
Study 17905237 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (n=72)
Number of subjects: 130
Study 17905237 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers (n=58)
Number of subjects: 130
Study 17919254 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent acrylic resilient denture liner dentures (RLD)
Number of subjects: 74
Study 17919254 — intervention group
Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin dentures (ARD)
Number of subjects: 74
Study 15297090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention by a specialized nutritional team (nurse and dietician)
Number of subjects: 212
Study 15297090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 212
Study 15297090 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard regime)
Number of subjects: 212
Study 15297090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention and control
Number of subjects: 212
Study 11718219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m THY
Number of subjects: 39
Study 11718219 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m MIBI
Number of subjects: 39
Study 9166128 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/m3 NMP
Number of subjects: 6
Study 9166128 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/m3 NMP
Number of subjects: 6
Study 9166128 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m3 NMP
Number of subjects: 6
Study 9166128 — intervention group
Group type: COMPARATOR
Intervention: NMP exposure
Number of subjects: 6
Study 7702974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (5 micrograms/kg/min) and isosorbide dinitrate (2 micrograms/kg/min) gated blood pool scintigraphy (GBPS)
Number of subjects: 38
Study 7702974 — intervention group
Group type: COMPARATOR
Intervention: Thallium SPECT with reinjection
Number of subjects: 38
Study 3312176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 84
Study 3312176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg
Number of subjects: 84
Study 3312176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 84
Study 3312176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 3312176 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (all doses)
Number of subjects: 84
Study 29258631 — intervention group
Group type: EXPERIMENTAL
Intervention: CBGT + ABM
Number of subjects: 50
Study 29258631 — intervention group
Group type: COMPARATOR
Intervention: CBGT + placebo
Number of subjects: 50
Study 26797232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 260
Study 26359996 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (54 to 64 U administered: GFL 20 U; HFL 10-20 U; LPL 24 U)
Number of subjects: 156
Study 26359996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 23514285 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of patent foramen ovale with the Amplatzer PFO Occluder
Number of subjects: 414
Study 23514285 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 414
Study 20829306 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (400 mg)
Number of subjects: 10
Study 20829306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18571340 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial therapies
Number of subjects: 2376
Study 17167363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent self‐catheterization (ISC)
Number of subjects: 40
Study 17167363 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheterization (SPC)
Number of subjects: 40
Study 15494910 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 500-mg dose of azithromycin
Number of subjects: 93
Study 15494910 — intervention group
Group type: COMPARATOR
Intervention: 1-week course of daily 200-mg dose of doxycycline
Number of subjects: 93
Study 11032403 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day IFN-beta injection (3 MU i.v. twice a day for 2 weeks)
Number of subjects: 30
Study 11032403 — intervention group
Group type: COMPARATOR
Intervention: Once-a-day IFN-beta injection (6 MU daily)
Number of subjects: 30
Study 11032403 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day IFN-beta injection
Number of subjects: 30
Study 8721257 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg riluzole
Number of subjects: 20
Study 8721257 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 20
Study 8721257 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg riluzole
Number of subjects: 20
Study 8721257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1578063 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention with follow-up telephone call
Number of subjects: 70
Study 1578063 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 3904894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (200 mg iodine/ml)
Number of subjects: 48
Study 3904894 — intervention group
Group type: COMPARATOR
Intervention: Angiografin (meglumine diatrizoate)
Number of subjects: 48
Study 31325240 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups
Number of subjects: 6
Study 31325240 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 6
Study 30287610 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reduction (stopping one antihypertensive medication) with optional self-monitoring
Number of subjects: 540
Study 30287610 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 540
Study 27052961 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months monitoring
Number of subjects: 142
Study 27052961 — intervention group
Group type: COMPARATOR
Intervention: 6 months monitoring
Number of subjects: 142
Study 25046730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of melatonin in soft gel capsules
Number of subjects: 60
Study 25046730 — intervention group
Group type: COMPARATOR
Intervention: 3 mg of melatonin powder
Number of subjects: 60
Study 20362711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab bolus application during PCI
Number of subjects: 1912
Study 20362711 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab application during PCI
Number of subjects: 1912
Study 20362711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of abciximab for 12 hours post-PCI
Number of subjects: 1912
Study 18267342 — intervention group
Group type: EXPERIMENTAL
Intervention: Echography assessment of tumors
Number of subjects: 2320
Study 18267342 — intervention group
Group type: EXPERIMENTAL
Intervention: Echography assessment for extrascleral extension
Number of subjects: 2320
Study 16699827 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and taurine pills
Number of subjects: 0
Study 16699827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12816784 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d iron supplement (ferrous sulfate)
Number of subjects: 430
Study 12816784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 11466801 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric and semi-parametric sample selection estimators
Number of subjects: 0
Study 11466801 — intervention group
Group type: EXPERIMENTAL
Intervention: Common support approach
Number of subjects: 0
Study 9097068 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week depression treatment trial
Number of subjects: 25
Study 9097068 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional courses of antidepressant therapy
Number of subjects: 25
Study 9097068 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study 8200383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant progestagen therapy
Number of subjects: 205
Study 8200383 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 205
Study 3808582 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate)
Number of subjects: 114
Study 3808582 — intervention group
Group type: COMPARATOR
Intervention: Control (no Healon)
Number of subjects: 114
Study 29654027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and intravenous antimicrobial prophylaxis
Number of subjects: 960
Study 29654027 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotic prophylaxis alone
Number of subjects: 960
Study 27741344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5% (3 formulations: DAP-11078, DAP-11079, DAP-11080), applied once daily
Number of subjects: 0
Study 27741344 — intervention group
Group type: COMPARATOR
Intervention: Dapsone gel, 5%, applied twice-daily
Number of subjects: 0
Study 27741344 — intervention group
Group type: EXPERIMENTAL
Intervention: All dapsone formulations (7.5% and 5%)
Number of subjects: 0
Study 24943000 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7034
Study 24943000 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7034
Study 24943000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7034
Study 24943000 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (both doses pooled)
Number of subjects: 7034
Study 23031516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu supplementation (15 mg Cu sulphate/kg dry matter)
Number of subjects: 10
Study 23031516 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented control
Number of subjects: 10
Study 19661830 — intervention group
Group type: EXPERIMENTAL
Intervention: High supervision (HS, 1:5 coach to athlete ratio)
Number of subjects: 124
Study 19661830 — intervention group
Group type: COMPARATOR
Intervention: Low supervision (LS, 1:25 coach to athlete ratio)
Number of subjects: 124
Study 18448618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dose of 10(7) fluorescent focus units (FFU) of a live attenuated influenza virus vaccine (CAIV‐T)
Number of subjects: 2172
Study 18448618 — intervention group
Group type: COMPARATOR
Intervention: Commercial inactivated influenza virus vaccine
Number of subjects: 2172
Study 18448618 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV‐T
Number of subjects: 2172
Study 15762092 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 512
Study 15762092 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 512
Study 12682327 — intervention group
Group type: EXPERIMENTAL
Intervention: Click-evoked vestibulo-ocular reflex test at 110dB
Number of subjects: 13
Study 12682327 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 13
Study 11864918 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone treatment
Number of subjects: 86
Study 11864918 — intervention group
Group type: COMPARATOR
Intervention: Control (no hormone treatment)
Number of subjects: 86
Study 10408993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of beta lactam antibiotics and erythromycin
Number of subjects: 0
Study 10408993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of clindamycin, tetracycline, trimethoprim/sulfamethoxazole, and ciprofloxacin
Number of subjects: 0
Study 10408993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized patients receiving multiple drugs
Number of subjects: 0
Study 10408993 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 7749974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 18
Study 7749974 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (60 mg)
Number of subjects: 18
Study 7749974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 18
Study 7749974 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (4 mg)
Number of subjects: 18
Study 7749974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7749974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg), Diphenhydramine (25 mg), Chlorpheniramine (4 mg)
Number of subjects: 18
Study 7749974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg) vs Chlorpheniramine (4 mg)
Number of subjects: 18
Study 2210597 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg isosorbide dinitrate in sustained-release form
Number of subjects: 25
Study 2210597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6171572 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (HLI) at a daily dose of 10(6) units applied by contraceptive pessary technique for 14 days in patients with viral alterations and 21 days in those with changed cytologic findings.
Number of subjects: 0
Study 6171572 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment).
Number of subjects: 0
Study 6205924 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon (300 mg three times daily)
Number of subjects: 12
Study 6205924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroquinidine Chloride (300 mg six times daily)
Number of subjects: 12
Study 6205924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29277963 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic foam mattress
Number of subjects: 15
Study 29277963 — intervention group
Group type: COMPARATOR
Intervention: Reactive gel mattress
Number of subjects: 15
Study 29277963 — intervention group
Group type: COMPARATOR
Intervention: Active alternating air mattress
Number of subjects: 15
Study 27552171 — intervention group
Group type: EXPERIMENTAL
Intervention: XiangBin granules
Number of subjects: 3
Study 27552171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 27552171 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 3
Study 24352484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 466
Study 24352484 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 466
Study 22935526 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose 600 mg
Number of subjects: 1457
Study 22935526 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel loading dose 300 mg
Number of subjects: 1457
Study 20810171 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex keratitis eyes
Number of subjects: 31
Study 20810171 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral unaffected eyes
Number of subjects: 31